                                                                    Exhibit 99.1

Advanced Biotherapy's CEO Receives Bioscience Leader of the Year Award

    LOS ANGELES--(BUSINESS WIRE)--Dec. 9, 2003--Advanced Biotherapy,
Inc. (OTCBB:ADVB) -- a developer of pioneering antibody therapies for
treating widespread autoimmune diseases -- reported that Edmond F.
Buccellato, Chief Executive Officer and Chairman of the Board of
Directors, received the "First Annual Healthcare Leadership Award" as
Bioscience Leader of the Year from the San Fernando Valley Business
Journal. The awards ceremony was held on December 3, 2003 at the
Warner Financial Center's Marriott Hotel in Woodland Hills,
California.
    Commenting on Mr. Buccellato's award, Mr. Thomas Pernice,
Secretary/Treasurer of the Board of Directors, stated, "On behalf of
the company and the Board of Directors, we congratulate Mr. Buccellato
for receiving this honor and commend him for his outstanding
leadership. We are very proud to have Mr. Buccellato receive this
recognition, particularly amongst such illustrious group of peers who
were considered." Mr. Pernice added, "We would also like to thank Mr.
Buccellato for his diligent work ethic and his very deep, personal
commitment to the company and its efforts to develop new therapies for
autoimmune diseases."
    Awards were granted to 10 individuals for outstanding leadership,
among 30 finalists in 10 healthcare categories including
biotechnology. The event was sponsored by UBS Financial Services Inc.
and Kaiser Permanente, among other firms at the awards ceremony.

    About Advanced Biotherapy

    Advanced Biotherapy, Inc., located in Los Angeles, with
laboratories in Columbia, Maryland, is pioneering the development of
new antibody therapies for treating severe and widespread autoimmune
diseases. Its investigational therapies attack autoimmune diseases at
their source, neutralizing biologic imbalances that impair immune
system function. Core technology is protected under U.S. patents and
patents pending for the exclusive use of a class of antibodies to the
protein known as interferon-gamma, and antibodies to other proteins,
for treating a range of autoimmune diseases.

    Statements made in this news release, other than statements of
historical fact, are forward-looking statements and are subject to a
number of uncertainties that could cause actual results to differ
materially from the anticipated results or other expectations
expressed in our forward-looking statements. The risks and
uncertainties which may affect the development, operations and results
of our business include, but are not limited to the following: risks
associated with clinical trials, the uncertainties of research and
product development programs, the uncertainties of the regulatory
approval process, the risks of competitive products, the risks of our
current capital resources, the uncertainties as to the availability of
future capital and our future capital requirements, and the risks
associated with the extent and breadth of the Company's patent
portfolio. The foregoing discussion of the pending clinical
investigations and the effect of the patents issued and pending
involves risks and uncertainties, including but not limited to the
risks that third parties may be successful in challenging such
patents; or that granted claims may be held invalid or interpreted
differently by a court of law; or that new technologies will be
developed that are superior in treating the diseases targeted by
Advanced Biotherapy, Inc. Readers are cautioned not to place reliance
on these forward-looking statements, which speak only as of the date
the statements were made. See the Company's public filings with the
Securities and Exchange Commission for further information about risks
and uncertainties that may affect the Company and the results or
expectations expressed in our forward-looking statements, including
the section captioned "Factors That May Affect The Company" contained
in the Company's Annual Report on Form 10-KSB/A for the fiscal year
ended December 31, 2002.

    CONTACT: Advanced Biotherapy, Inc.
             Amy Buccellato, 818-883-6716
             www.advancedbiotherapy.com





